- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
August 1, 2022Marc Betinsky Appointed to Magistrate Judge Merit Selection Panel
-
July 28, 2022Jake Holdreith, Robins Kaplan Shortlisted For LMG Life Sciences Awards
-
July 28, 2022Meegan Hollywood Named to Bloomberg Law’s 2022 “They’ve Got Next: The 40 Under 40” List
-
August 18, 2022Annual Robins Kaplan MAJ Welcome Reception
-
September 9, 2022LGBTQ Legal Services: Transgender Name Change Clinic
-
September 10, 2022Children’s Theatre Company 2022 Curtain Call Ball
-
Second QuarterANDA Approvals
-
Second QuarterGeneric Launches
-
July 19, 2022Briefly: What to do with a Reverse and Remand
-
August 5, 2022All Eyes on July Jobs Report Following Fed Rate Hikes
-
August 4, 2022Walmart to Cut 200 Corporate Positions Following Lowered Profit Forecasts
-
August 3, 2022Robinhood Cuts Workforce by 23% to Counter Ill-Advised Expansion
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
GENERICally Speaking Hatch Waxman Bulletin
The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
The Summer 2022 issue of the GENERICally Speaking email campaign provides you and your company with some of the knowledge beneficial to remaining attentive to the complexity of ANDA patent litigation.
In this issue we review Q2 cases and issue(s) presented:
- Novartis Pharms. Corp. v. Accord Healthcare, Inc.
Gilenya® (fingolimod HCl)
The Federal Circuit granted Defendants’ petition for panel rehearing, vacated its prior decision, and reversed the district court’s judgment that the asserted claims were not invalid for inadequate written description. - Bausch Health Ireland, Ltd. v. Padagis Israel Pharms., Ltd.
Duobrii® (halobetasol propionate / tazarotene)
The court granted summary judgment of no inequitable conduct. - Astellas US LLC v. Hospira, Inc.
Lexiscan® (regadenoson)
After bench trial, the Court found that the patents-in-suit were not infringed by Hospira.
Relevant ANDA updates highlighted in this issue:
Related Professionals
New Drug Applications and 505(b)(2) Applications
Abbreviated New Drug Applications and 505(b)(2) Applications
Reported settlements in federal district court cases
Federal district court cases that are filed pursuant to the Hatch-Waxman Act
Gilenya® (fingolimod HCl)
Duobrii® (halobetasol propionate / tazarotene)
Lexiscan® (regadenoson)
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.